It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancer-associated fibroblasts (CAFs) have emerged as a dominant non-hematopoietic cell population in the tumour microenvironment, serving diverse functions in tumour progression. However, the mechanisms via which CAFs influence the anti-tumour immunity remain poorly understood. Here, using multiple tumour models and biopsies from cancer patients, we report that α-SMA+ CAFs can form immunological synapses with Foxp3+ regulatory T cells (Tregs) in tumours. Notably, α-SMA+ CAFs can phagocytose and process tumour antigens and exhibit a tolerogenic phenotype which instructs movement arrest, activation and proliferation in Tregs in an antigen-specific manner. Moreover, α-SMA+ CAFs display double-membrane structures resembling autophagosomes in their cytoplasm. Single-cell transcriptomic data showed an enrichment in autophagy and antigen processing/presentation pathways in α-SMA-expressing CAF clusters. Conditional knockout of Atg5 in α-SMA+ CAFs promoted inflammatory re-programming in CAFs, reduced Treg cell infiltration and attenuated tumour development. Overall, our findings reveal an immunosuppressive mechanism entailing the formation of synapses between α-SMA+ CAFs and Tregs in an autophagy-dependent manner.
Cancer-associated fibroblasts (CAFs) are a predominant stromal cell population in the tumour microenvironment. Here, the authors demonstrate that αSMA + CAFs can form an immunological synapse with regulatory T cells (Tregs) in tumours, which results in Treg activation and expansion in a process that is antigen- and autophagy-dependent.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Biomedical Research Foundation Academy of Athens, Center of Clinical, Experimental Surgery & Translational Research, Athens, Greece (GRID:grid.417975.9) (ISNI:0000 0004 0620 8857); University of Crete, Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, Heraklion, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437)
2 University of Crete, Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, Heraklion, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437); Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, Heraklion, Greece (GRID:grid.4834.b) (ISNI:0000 0004 0635 685X)
3 University of Oxford, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Biomedical Research Foundation Academy of Athens, Center of Clinical, Experimental Surgery & Translational Research, Athens, Greece (GRID:grid.417975.9) (ISNI:0000 0004 0620 8857)
5 Biomedical Research Foundation Academy of Athens, Center of Basic Research, Athens, Greece (GRID:grid.417975.9) (ISNI:0000 0004 0620 8857)
6 Attikon University Hospital, 2nd Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
7 JJP Biologics, Warsaw, Poland (GRID:grid.5216.0)
8 University of Crete, Electron Microscopy Laboratory, Heraklion, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437)
9 Biomedical Sciences Research Centre Alexander Fleming, Institute for Bioinnovation, Athens, Greece (GRID:grid.424165.0) (ISNI:0000 0004 0635 706X)
10 Medical School National and Kapodistrian University of Athens, Laboratory of Biology, School of Medicine, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
11 Medical School National and Kapodistrian University of Athens, Laboratory of Biology, School of Medicine, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800); University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Institute for Clinical Chemistry and Laboratory Medicine, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
12 University of Oxford, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Medical School National and Kapodistrian University of Athens, Laboratory of Biology, School of Medicine, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
13 Biomedical Research Foundation Academy of Athens, Center of Clinical, Experimental Surgery & Translational Research, Athens, Greece (GRID:grid.417975.9) (ISNI:0000 0004 0620 8857); University of Crete, Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, Heraklion, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437); Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, Heraklion, Greece (GRID:grid.4834.b) (ISNI:0000 0004 0635 685X); University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Institute for Clinical Chemistry and Laboratory Medicine, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)